REG - Physiomics PLC - Contract announcement

PhysiomicsAnnouncement

11/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230111:nRSK2920Ma&default-theme=true

RNS Number : 2920M  Physiomics PLC  11 January 2023

11 January 2023

 

Physiomics plc

("Physiomics") or ("the Company")

 

Contract announcement

 

Physiomics plc (AIM: PYC), the consultancy using mathematical models to
support the development of drug treatment regimens and personalised medicine
solutions, is pleased to announce that it has entered into a further contract
with its existing client Cancer Research UK.

 

Physiomics was first retained in July 2019 by Bicycle Therapeutics and Cancer
Research UK to conduct Pharmacokinetics (PK), analyses (what the body does to
the drug) of clinical data arising from the Cancer Research UK-sponsored Phase
I/IIa clinical trial in solid tumours with the Bicycle Therapeutics' program,
BT1718.

 

The follow-on project announced today will be contracted directly with Cancer
Research UK and represents the second such directly contracted project
following the award completion last month of a contract for PKPD
(pharmacodynamics, what the drug does to the body) modelling relating to the
Cancer Research UK-sponsored clinical trial of ALETA-001, a CAR-T cell engager
candidate for the treatment of blood cancers developed by Aleta
Biotherapeutics.

 

The project is expected to be completed during Q1 2023.

 

Dr Jim Millen, CEO of Physiomics, commented:

"We are very pleased to be working on this second project with Cancer Research
UK, the UK's leading cancer research charity and look forward to developing
our relationship further going forwards."

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEBLFFXFLEBBV